OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Erickson on the Varying Safety Profiles of Select PARP Inhibitors in Ovarian Cancer

December 7th 2021

Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer.

Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC

December 7th 2021

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Dr. Boland on Determining When to Utilize Up-front Perioperative Chemotherapy in CRC

December 6th 2021

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

Dr. Anders on Navigating the Treatment Landscape of Metastatic TNBC

December 6th 2021

Carey K. Anders, MD, discusses navigating the treatment landscape of metastatic triple-negative breast cancer.

Dr. Bestvina on Challenges With Interpreting Molecular Reports in Lung Cancer

December 6th 2021

Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.

Dr. Qin on Treatment Considerations for Immunotherapy in NSCLC

December 6th 2021

Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.

Dr. Qin on Selecting Single-Agent Immunotherapy or Chemoimmunotherapy in NSCLC

December 3rd 2021

Angel Qin, MD, discusses selecting between single-agent immunotherapy or combination chemoimmunotherapy in non–small cell lung cancer.

Dr. Iqbal on Determining Whether to Start With Regorafenib or TAS-102 in mCRC

December 3rd 2021

Syma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Bupathi on the Evolving Treatment Landscape of Bladder Cancer

December 3rd 2021

Manojkumar Bupathi, MD, MS, discusses the evolving treatment landscape of bladder cancer.

Dr. Raghav on Treatment Considerations With Regorafenib and TAS-102 in CRC

December 3rd 2021

Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer.

Dr. Grivas on Enfortumab Vedotin in Second- and Third-Line Urothelial Carcinoma

December 3rd 2021

Petros Grivas, MD, PhD, discusses the utility of enfortumab vedotin-ejfv in the second- and third-line setting for patients with urothelial carcinoma.

Dr. Leal on the Evolution of Treatment in EGFR Exon 20 Insertion+ NSCLC

December 2nd 2021

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Pothuri on the Challenges of POLE Testing in Endometrial Cancer

December 2nd 2021

Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer.

Dr. Lee on Treatment Considerations in Smoldering Multiple Myeloma

December 2nd 2021

Sarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.

Dr. Rose on the Importance of Genetic Testing in Ovarian Cancer

December 2nd 2021

Stephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.

Dr. Allison on the Urgency of Drug Development in Oncology

December 2nd 2021

James P. Allison, PhD, discusses his experience with the urgency of drug development in oncology.

Dr. Thaker on the Importance of Surveying Patients on Unmet Needs in Ovarian Cancer

December 2nd 2021

Premal Thaker, MD, MS, discusses the importance of surveying patients on unmet needs in ovarian cancer.

Dr. Luke on Toxicities With Targeted Therapy Vs Immunotherapy in Melanoma

December 1st 2021

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma.

Dr. Chauncey on Isatuximab Combinations in Multiple Myeloma

December 1st 2021

Thomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.

Dr. Garon on the Potential Clinical Implications of the TROPION-Lung01 Trial in NSCLC

December 1st 2021

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.